300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Social Impact
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Theatre
Medical
Recruiting
Web3
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Oceania
Oman
Puerto Rico
Poland
Andorra
Cameroon
Guernsey
Sudan
Colombia
Armenia
China
Costa Rica
Czech Republic
Kuwait
Kenya
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Canada
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
United Kingdom
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Hugo Harrod, Partner at MVM Life Science Partners

Hugo Harrod

Partner @ MVM Life Science Partners

London, United Kingdom

Hugo Harrod is a funding round investor at MVM Life Science Partners in London focused on Medical and Health Care. Hugo Harrod is based out of London, England and is the Board of Director of ProVerum Medical. and also Partner of MVM Life Science Partners. Hugo previously worked at AccuVein as a Board Member. Hugo Harrod attended the University of Oxford.

Total investments:
9
Last investment:
Lead investor:
56%

Last updated:

Industries Hugo Harrod invests in

MedicalHealth CareMedical DeviceBiotechnologyGenetics

Stages Hugo Harrod invests in

Funding RoundSeries BSeries CSeries EVenture - Series Unknown

Countries Hugo Harrod invests in

United StatesUnited KingdomGermanyIreland

Investment Focus

Industry

  • Medical 4 (44%)
  • Health Care 4 (44%)
  • Medical Device 4 (44%)
  • Biotechnology 3 (33%)
  • Genetics 1 (11%)
See all 10 industries →

Stage

  • Funding Round 4 (44%)
  • Series B 2 (22%)
  • Series C 1 (11%)
  • Series E 1 (11%)
  • Venture - Series Unknown 1 (11%)

Country

  • United States 3 (33%)
  • United Kingdom 2 (22%)
  • Germany 1 (11%)
  • Ireland 1 (11%)

Investments

CompanyDescriptionRoundLinks
ProVerum Medical ProVerum Medical
ProVerum Medical is a healthcare company that develops innovative treatments for benign prostatic hyperplasia (BPH). ProVerum develops the ProVee System, which is a minimally invasive implant that gently opens the blocked part of the urethra without cutting, heating, or removing tissue. $80M / Series B / Aug 25, 2025
Nalu Medical Nalu Medical
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California. $85M / Series E / Jan 03, 2024
Gynesonics Gynesonics
Gynesonics is a women’s healthcare company focused on the development of advanced incision-free solutions for the treatment of uterine conditions. Gynesonics serves customers worldwide. It was founded in 2005 and is headquartered in Redwood City, California. $42.5M / Oct 25, 2023
Nalu Medical Nalu Medical
Nalu Medical is an early-stage company that develops a range of medical devices. Their vision to modernize and improve the technology in medical devices, thus improving the lives of people.The Nalu neurostimulation system is a battery-free, micro-implantable pulse generator (iPG) currently cleared by the FDA for both Spinal Cord Stimulation (SCS)and Peripheral Nerve Stimulation (PNS) for mitigating chronic pain. The company was founded in 2014 and is based in Carlsbad, California. $104M / Venture - Series Unknown / Feb 17, 2022
Vertos Medical Vertos Medical
Vertos Medical is a healthcare company that offers medical devices used in the treatment of common spinal diseases. The company commercializes the percutaneous treatment for lumbar spinal stenosis (LSS). It also offers minimally invasive lumbar decompression devices for the treatment of various forms of LSS. The company offers its devices in theUnited States. Vertos Medical was founded by Dr. Dave Solsberg and Dr. Don Schomer in 2005 and is headquartered in Aliso Viejo, California. $28M / Jun 12, 2017
Horizon Discovery Horizon Discovery
Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline. $8.8M / Jun 03, 2013
Horizon Discovery Horizon Discovery
Horizon Discovery Group PLC is a UK life science company that uses gene editing and gene modulation platforms to produce cells, applying them in research and clinical applications that advance human health. The Company’s gene editing and gene modulation platform, are able to alter almost any DNA sequence or RNA transcription, has generated acatalogue of over 1,000,000 cell and reagent products that help researchers recapitulate the genetic and protein anomalies found in diseases like cancer. These models have been adopted by c12, 000 organizations to better understand of the predictors and drivers of disease and drug response, and by Horizon in a range of services offered to customers, as well as in the Company’s own research R&D pipeline. $14.4M / Series C / Sep 13, 2011
Vantia Therapeutics Vantia Therapeutics
Vantia Therapeutics is an emerging pharmaceutical company developing novel, small molecule drugs targeting large areas of unmet medical need. Its strong clinical pipeline includes VA106483 for nocturia and VA111913 for dysmenorrhoea, which directly target indications that together affect many millions of people, are poorly treated and representbillion dollar markets. Vantia's strategy is to develop its proprietary drug candidates through Phase II clinical testing and then commercialise through partnerships. The Company was founded in 2008 and is backed by specialist life science investors Novo A/S, SV Life Sciences and MVM Life Science Partners. $6.5M / Series B
eZono eZono
eZono is a young dynamic company focused on point of care solutions. Based in Jena, Germany, eZono brings together a multicultural team of experts, bringing a diverse and fresh approach to ultrasound guidance of interventional procedures.Founded in 2004, eZono AG is a different kind of ultrasound company, one that empowers non-traditionalultrasound users to incorporate sonography in their daily work. This enables their customers to improve clinical outcomes, enhance patient satisfaction and in particular lower cost. As a result they bring not only affordable portable sonography technology to specific applications but also makes it easy for instance for anesthetists to operate – reducing drastically their learning effort. $10M

Co-Investors

MVM Life Science Partners

About MVM Life Science Partners

VC Fund · London, United Kingdom

MVM manages four funds totaling more than US$700 million. MVM has invested in biopharmaceuticals, diagnostics, drug delivery, gene therapy, healthcare services, medical devices, OTC medicines, research tools and vaccines.

MVM Life Science Partners Contacts

NameEmailPhoneSocials
Anna Norrington
Anna Norrington Head of Investor Communications
Hugo Harrod
Hugo Harrod Partner
Neil Akhurst
Neil Akhurst Finance Partner
Stephen Reeders
Stephen Reeders Founder & Managing Partner
Stephen Reeders
Stephen Reeders Founder & Managing Partner

Sign up to unlock verified contacts

Unlock Contacts
Open MVM Life Science Partners full profile

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Social Impact
Retail
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Theatre
Medical
Recruiting
Web3
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Zambia
Norway
Tajikistan
Mexico
Nigeria
Russian Federation
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Romania
Oceania
Oman
Puerto Rico
Poland
Andorra
Cameroon
Guernsey
Sudan
Colombia
Armenia
China
Costa Rica
Czech Republic
Kuwait
Kenya
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Botswana
Paraguay
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Canada
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Argentina
Bangladesh
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
United Kingdom
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Hugo Harrod invest in?

Hugo Harrod invests primarily in Medical, Health Care and Medical Device startups, most often at Funding Round and Series B stage. Most of the 9 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Hugo Harrod last invest?

The most recent investment recorded for Hugo Harrod closed in Aug 2025. Shizune tracks 9 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Hugo Harrod Hugo Harrod Find email